Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13

作者：

Devlies, Wout ^{[1
,2
]}

Eckstein, Markus ^{[3
]}

Cimadamore, Alessia ^{[4
]}

Devos, Gaetan ^{[1
]}

Moris, Lisa ^{[1
,2
]}

van den Broeck, Thomas ^{[1
]}

Montironi, Rodolfo ^{[4
]}

Joniau, Steven ^{[1
]}

Claessens, Frank ^{[2
]}

Gevaert, Thomas ^{[5
]}

机构：

[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium

[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium

[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany

[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy

[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium

来源：

CELLS | 2020年 / 9卷 / 11期

关键词：

prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;

D O I：

10.3390/cells9112494

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

引用

页码：1 / 13

页数：13

共 50 条

[21] HTA and Reimbursement Status of Metastatic Hormone-Sensitive Prostate Cancer, Nonmetastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
Bencina, Goran
Petrova, Elina
Sonmez, Demet
Pereira, Sonia Matos
Dimitriadis, Ioannis
Salomonsson, Stina
JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (01): : 102 - 110
[22] Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other
Alanazi, Ibrahim O.
Al Shehri, Zafer S.
Ebrahimie, Esmaeil
Giahi, Hassan
Mohammadi-Dehcheshmeh, Manijeh
MOLECULAR CARCINOGENESIS, 2019, 58 (06) : 862 - 874
[23] Olaparib in Metastatic Castration-Resistant Prostate Cancer
Biswas, Bivas
Ganguly, Sandip
Ghosh, Joydeep
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1174 - 1175
[24] Biomarkers in Metastatic Castration-resistant Prostate Cancer
Miller, K.
AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
[25] Olaparib in metastatic castration-resistant Prostate Cancer
Lorenz, Judith
AKTUELLE UROLOGIE, 2022, 53 (02)
[26] The obesity paradox in metastatic castration resistant prostate cancer
Cirulli, G. O.
Martini, A.
Sfakianos, J. P.
Gandaglia, G.
Fossati, N.
Stabile, A.
Cucchiara, V.
Mazzone, E.
Necchi, A.
Karakiewicz, P. I.
Briganti, A.
Montorsi, F.
Oh, W. K.
Gallagher, E. D.
Galsky, M. D.
EUROPEAN UROLOGY, 2021, 79 : S1195 - S1196
[27] Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Olmos, D.
Thiery-Vuillemin, A.
Twardowski, P.
Mehra, N.
Goessl, C.
Kang, J.
Burgents, J.
Wu, W.
Kohlmann, A.
Adelman, C. A.
Hussain, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
[28] Advances in metastatic castration-resistant prostate cancer
Kentepozidis, Nikolaos
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
[29] Rucaparib in castration-resistant, metastatic prostate cancer
Lorenz, Judith
AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
[30] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Rodrigues, Daniel Nava
Mehra, Niven
Figueiredo, Ines
Crespo, Mateus
Riisnaes, Ruth
Miranda, Susana A. A.
Ferreira, Ana
Tunariu, Nina
Perez-Lopez, Raquel
Boysen, Gunther
Sharp, Adam
Bianchini, Diletta
Kolinsky, Michael
Rescigno, Pasquale
Zafeiriou, Zafetris
Mateo, Joaquin
De Bono, Johann S.
MODERN PATHOLOGY, 2016, 29 : 251A - 251A

← 1 2 3 4 5 →